Clinical Trial Update: Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating camrelizumab plus famitinib malate for recurrent/metastatic cervical cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Famitinib malate (famitinib malate)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Cervical Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING